Prosonix, a speciality pharmaceutical company based in Oxford in the UK, which is developing a portfolio of inhaled respiratory medicines, has appointed Frank Condella as Non-executive Director.
Condella has more than 30 years of business experience, including senior leadership roles in both privately and publicly held companies in the pharmaceutical and healthcare industry, and particularly in the development and commercialisation of respiratory medicines.
Condella is President and Chief Executive of Columbia Laboratories, a NASDAQ-listed speciality pharmaceutical company, and Non-executive Chairman of Skyepharma plc, a London-listed speciality drug delivery company. He was CEO of Skyepharma between 2006 and 2008, President of European Operations and Managing Director, UK at IVAX Corporation from 2002 to 2006, and President and Chief Executive of Faulding Pharmaceutical from 2000 to 2001.
Previously, he was Vice-President of Specialty Care Products at Roche and Vice-President and General Manager of the Lederle unit of American Home Products (now part of Pfizer).
Condella said: ‘Prosonix has developed a unique platform for developing generic and novel respiratory medicines based on engineering drug particles whose fundamental properties are designed specifically for inhalation via simple inhalation devices. This approach could lead to the availability of the first directly substitutable generic respiratory medicines, as well as novel combination products with enhanced performance and cost benefits. Prosonix is a very exciting company and I am very much looking forward to working with the company during this transformational phase of its development.’